Alexander Spira

Alexander Spira

UNVERIFIED PROFILE

Are you Alexander Spira?   Register this Author

Register author
Alexander Spira

Alexander Spira

Publications by authors named "Alexander Spira"

Are you Alexander Spira?   Register this Author

44Publications

1428Reads

26Profile Views

A review of canakinumab and its therapeutic potential for non-small cell lung cancer.

Anticancer Drugs 2019 Oct;30(9):879-885

Johns Hopkins School of Medicine, Baltimore, Maryland.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1097/CAD.0000000000000832DOI Listing
October 2019

Brigatinib versus Crizotinib in ALK-Positive Non-Small-Cell Lung Cancer.

N Engl J Med 2018 11 25;379(21):2027-2039. Epub 2018 Sep 25.

From the University of Colorado Cancer Center, Aurora (D.R.C.); Division of Medical Oncology, Department of Internal Medicine, Yonsei Cancer Center, Yonsei University College of Medicine (H.R.K.), Samsung Medical Center (M.-J.A.), and Seoul National University Hospital (D.-W.K.), Seoul, National Cancer Center, Goyang (J.-Y.H.), Seoul National University Bundang Hospital, Seongnam (J.-S.L.), and Chungbuk National University Hospital, Chungbuk National University College of Medicine, Cheongju (K.H.L.) - all in South Korea; National Taiwan University Hospital (J.C.-H.Y.) and the Faculty of Medicine, School of Medicine, National Yang-Ming University (G.-C.C.), Taipei, and the Division of Chest Medicine, Department of Internal Medicine, Taichung Veterans General Hospital, Taichung (G.-C.C.) - all in Taiwan; the Ludwig Boltzmann Institute for COPD and Respiratory Epidemiology, Department of Respiratory and Critical Care Medicine, Otto Wagner Hospital, Vienna (M.J.H.); Queen Elizabeth Hospital, Kowloon, Hong Kong (J.Y.-C.L.); Azienda Ospedaliera S. Giuseppe Moscati, Avellino (C.G.), the Scientific Institute of Romagna for the Study and Treatment of Cancer, Meldola (A.D.), Centro di Riferimento Oncologico, Istituto Nazionale Tumori, IRCCS Struttura Operativa Complessa Oncologia Medica A, Aviano (A.B.), Thoracic Medical Oncology, Istituto Nazionale Tumori, IRCCS Fondazione G. Pascale, Naples (A.M.), and the Medical Oncology Unit, University Hospital of Parma, Parma (M.T.) - all in Italy; Complejo Hospitalario Universitario de A Coruña, Coruña (R.G.C.), and Vall d'Hebron University Hospital, Barcelona (E.F.) - both in Spain; the Department of Hematology and Oncology, University Department of Internal Medicine-Oncology, Pius-Hospital Medical Campus, University of Oldenburg, Oldenburg, Germany (F.G.); the Department of Medical Oncology, Christie NHS Foundation Trust, and Division of Cancer Sciences, University of Manchester, Manchester (R.C.), and Guy's and St. Thomas' NHS Foundation Trust (S.G.) and Royal Marsden Hospital and the National Heart and Lung Institute, Imperial College London (S.P.), London - all in the United Kingdom; Virginia Cancer Specialists Research Institute and US Oncology Research, The Woodlands, TX (A.S.); Yale Cancer Center, New Haven, CT (S.N.G.); and Millennium Pharmaceuticals, Cambridge, MA (N.G., J.H., D.K.).

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1056/NEJMoa1810171DOI Listing
November 2018

Management of Immune-Related Adverse Events in Patients Treated With Immune Checkpoint Inhibitor Therapy: American Society of Clinical Oncology Clinical Practice Guideline.

J Clin Oncol 2018 06 14;36(17):1714-1768. Epub 2018 Feb 14.

Julie R. Brahmer, Johns Hopkins Kimmel Cancer Center; Jennifer S. Mammen, Johns Hopkins University, Baltimore, MD; Christina Lacchetti, American Society of Clinical Oncology, Alexandria; Alexander Spira, Virginia Cancer Specialists and US Oncology Research, Fairfax, VA; Bryan J. Schneider, University of Michigan Health System, Ann Arbor, MI; Michael B. Atkins, Georgetown Lombardi Comprehensive Cancer Center; Cristina A. Reichner, Georgetown University; Laura D. Porter, Colon Cancer Alliance; Washington, DC; Kelly J. Brassil, Aung Naing, Loretta J. Nastoupil, Maria E. Suarez-Almazor, and Yinghong Wang, MD Anderson Cancer Center, Houston, TX; Jeffrey M. Caterino, The Ohio State University Wexner Medical Center, Columbus, OH; Ian Chau, The Royal Marsden Hospital and Institute of Cancer Research, London and Surrey, United Kingdom; Marc S. Ernstoff and Igor Puzanov, Roswell Park Cancer Institute, Buffalo; Bianca D. Santomasso and Jedd D. Wolchok, Memorial Sloan Kettering Cancer Center; Jeffrey S. Weber, New York University Langone Medical Center, New York, NY; Pamela Ginex, Oncology Nursing Society, Pittsburgh, PA; Jennifer M. Gardner, Seattle Cancer Care Alliance and University of Washington, Seattle, WA; Sigrun Hallmeyer, Oncology Specialists SC, Park Ridge, IL; Jennifer Holter Chakrabarty, University of Oklahoma, Stephenson Cancer Center, Oklahoma City, OK; Natasha B. Leighl, Princess Margaret Cancer Centre, Toronto, Ontario, Canada; David F. McDermott, Beth Israel Deaconess Medical Center; Carole Seigel, Massachusetts General Hospital Cancer Center, Boston, MA; John A. Thompson, Seattle Cancer Care Alliance, University of Washington, and the Fred Hutchinson Cancer Research Center, Seattle, WA; and Tanyanika Phillips, CHRISTUS St Frances Cabrini Cancer Center, Alexandria, LA.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1200/JCO.2017.77.6385DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC6481621PMC
June 2018

Innovations in Clinical Trial Design in the Era of Molecular Profiling.

Methods Mol Biol 2017 ;1606:19-36

Center for Applied Proteomics and Molecular Medicine, Institute for Advanced Biomedical Research, George Mason University, 10920 George Mason Circle, Manassas, VA, 20110, USA.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1007/978-1-4939-6990-6_2DOI Listing
February 2018

Product review on the Anti-PD-L1 antibody atezolizumab.

Hum Vaccin Immunother 2018 02 20;14(2):269-276. Epub 2017 Dec 20.

b Virginia Cancer Specialists Research Institute , Fairfax , VA , USA.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1080/21645515.2017.1403694DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC5806639PMC
February 2018

Prospects and progress of atezolizumab in non-small cell lung cancer.

Expert Opin Biol Ther 2017 06 28;17(6):781-789. Epub 2017 Mar 28.

e US Oncology Thoracic Oncology Program , Virginia Cancer Specialists , Fairfax , VA 22031.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1080/14712598.2017.1309389DOI Listing
June 2017

A brief review of the management of platinum-resistant-platinum-refractory ovarian cancer.

Med Oncol 2017 Jun 25;34(6):103. Epub 2017 Apr 25.

Baptist Health Medical Group, Gynecologic Oncology, Lexington, KY, USA.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1007/s12032-017-0960-zDOI Listing
June 2017

Efficacy and Safety Results of the Afatinib Expanded Access Program.

Oncol Ther 2017 10;5(1):103-110. Epub 2017 Apr 10.

Department of Solid Tumor Oncology and Investigational Therapeutics, Levine Cancer Institute, Carolinas HealthCare System, Charlotte, NC USA.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1007/s40487-017-0043-5DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC5488108PMC
April 2017

Docetaxel As Monotherapy or Combined With Ramucirumab or Icrucumab in Second-Line Treatment for Locally Advanced or Metastatic Urothelial Carcinoma: An Open-Label, Three-Arm, Randomized Controlled Phase II Trial.

J Clin Oncol 2016 05 29;34(13):1500-9. Epub 2016 Feb 29.

Daniel P. Petrylak, Yale University Cancer Center, New Haven, CT; Scott T. Tagawa, Weill Cornell Medical College, New York; David Shaffer, New York Oncology Hematology, Albany, NY; Manish Kohli, Mayo Clinic, Rochester, MN; Andrea Eisen, Sunnybrook Health Sciences Centre; Srikala S. Sridhar, Princess Margaret Hospital, Toronto; Christina Canil, Ottawa Hospital Cancer Centre, Ottawa, Ontario; Kim N. Chi, British Columbia Cancer Agency, Vancouver, British Columbia, Canada; Alexander Spira, Virginia Cancer Specialists, Fairfax, VA; Alexander Spira, John M. Burke, David Shaffer, and Nicholas J. Vogelzang, US Oncology Research, The Woodlands, TX; Evan Y. Yu, University of Washington Medical Center and Fred Hutchinson Cancer Research Center, Seattle, WA; John M. Burke, Rocky Mountain Cancer Centers, Aurora, CO; Chong-Xian Pan, University of California-Davis Medical Center, Sacramento; David I. Quinn, University of Southern California Norris Comprehensive Cancer Center, Los Angeles, CA; Jenny J. Kim, Johns Hopkins University, Baltimore, MD; Jeanny B. Aragon-Ching, George Washington University Medical Center, Washington, DC; Nicholas J. Vogelzang, Comprehensive Cancer Centers of Nevada, Las Vegas, NV; Shande Tang, Hui Zhang, Christopher T. Cavanaugh, Ling Gao, and John S. Kauh, Eli Lilly, Bridgewater, NJ; and Richard A. Walgren, Eli Lilly, Indianapolis, IN.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1200/JCO.2015.65.0218DOI Listing
May 2016

Efficacy and Safety of Trabectedin or Dacarbazine for Metastatic Liposarcoma or Leiomyosarcoma After Failure of Conventional Chemotherapy: Results of a Phase III Randomized Multicenter Clinical Trial.

J Clin Oncol 2016 Mar 14;34(8):786-93. Epub 2015 Sep 14.

George D. Demetri, Dana-Farber Cancer Institute and Ludwig Center at Harvard, Boston, MA; Margaret von Mehren, Fox Chase Cancer Center; Arthur Staddon, University of Pennsylvania, Philadelphia; Hussein Tawbi, University of Pittsburgh Cancer Institute, Pittsburgh, PA; Robin L. Jones, Seattle Cancer Care Alliance, Seattle, WA; Martee L. Hensley, Memorial Sloan Kettering Cancer Center; Robert G. Maki, Mount Sinai Medical Center, New York, NY; Scott M. Schuetze, University of Michigan, Ann Arbor, MI; Mohammed Milhem, University of Iowa Hospitals and Clinics, Iowa City, IA; Anthony Elias, University of Colorado Cancer Center, Aurora, CO; Kristen Ganjoo, Stanford Hospital and Clinics, Stanford, CA; Brian A. Van Tine, Washington University in St Louis, St Louis, MO; Alexander Spira, Virginia Cancer Specialists, Fairfax, VA; Andrew Dean, St John of God Hospital-Bendat Cancer Centre, Subiaco, Western Australia, Australia; Nushmia Z. Khokhar, Youn Choi Park, Roland E. Knoblauch, and Trilok V. Parekh, Janssen Research & Development, Raritan, NJ; and Shreyaskumar R. Patel, The University of Texas MD Anderson Cancer Center, Houston, TX.

View Article

Download full-text PDF

Source
http://ascopubs.org/doi/10.1200/JCO.2015.62.4734
Publisher Site
http://dx.doi.org/10.1200/JCO.2015.62.4734DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC5070559PMC
March 2016

Alectinib in Crizotinib-Refractory ALK-Rearranged Non-Small-Cell Lung Cancer: A Phase II Global Study.

J Clin Oncol 2016 Mar 23;34(7):661-8. Epub 2015 Nov 23.

Sai-Hong Ignatius Ou, University of California Irvine School of Medicine, Orange, CA; Jin Seok Ahn, Sungkyunkwan University School of Medicine; Luigi De Petris, Karolinska Institute and Karolinska University Hospital, Stockholm, Sweden; Ramaswamy Govindan, Washington University School of Medicine, St Louis, MO; James Chih-Hsin Yang, National Taiwan University, Taipei, Taiwan; Brett Hughes, The Prince Charles Hospital, Chermside, and University of Queensland, Queensland, Australia; Hervé Lena, Centre Hospitalier Universitaire de Rennes, Rennes; Denis Moro-Sibilot, Centre Hospitalier Universitaire de Grenoble, Institut National de la Santé et de la Recherche Médicale U823, Grenoble, France; Alessandra Bearz, National Cancer Institute, Aviano, Italy; Santiago Viteri Ramirez, Quiron-Dexeus University Hospital, Barcelona, Spain; Tarek Mekhail, Florida Hospital Cancer Institute, Orlando, FL; Alexander Spira, Virginia Cancer Specialists, Fairfax, VA; and Walter Bordogna, Bogdana Balas, Peter N. Morcos, Annabelle Monnet, and Ali Zeaiter, F. Hoffmann-La Roche, Basel, Switzerland; Dong-Wan Kim, Seoul National University Hospital, Seoul, South Korea.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1200/jco.2016.34.4_suppl.661DOI Listing
March 2016

A randomized, phase 2 trial of Docetaxel with or without PX-866, an irreversible oral phosphatidylinositol 3-kinase inhibitor, in patients with relapsed or metastatic non-small-cell lung cancer.

J Thorac Oncol 2014 Jul;9(7):1031-5

*Beth Israel Hospital, St. Luke's Hospital, Mount Sinai Health System, New York, New York; †Virginia Cancer Specialists, Fairfax, Virginia; ‡US Oncology Research, The Woodlands, Texas; §Abramson Cancer Center of the University of Pennsylvania, Philadelphia, Pennsylvania; ‖Northwest Cancer Specialists, Portland, Oregon; ¶Division of Medical Oncology, University of Colorado School of Medicine, Aurora, Colorado; #University of Pittsburgh Cancer Institute, Pittsburgh, Pennsylvania; **Oncothyreon Inc., Seattle, Washington; ††Mary Crowley Cancer Research Centers, Dallas, Texas; ‡‡Johns Hopkins University, Baltimore, Maryland; Memorial Sloan Kettering Cancer Center, New York, New York; §§New York-Presbyterian Hospital, Columbia University Medical Center, New York, New York; and ‖‖Section of Hematology/Oncology, Denver Veterans Affairs Medical Center, Denver, Colorado.

View Article

Download full-text PDF

Source
https://linkinghub.elsevier.com/retrieve/pii/S15560864153033
Publisher Site
http://dx.doi.org/10.1097/JTO.0000000000000183DOI Listing
July 2014

Clinical trial design in the age of molecular profiling.

Methods Mol Biol 2012 ;823:19-34

Virginia Cancer Specialists, Fairfax, VA, USA.

View Article

Download full-text PDF

Source
http://link.springer.com/10.1007/978-1-60327-216-2_2
Publisher Site
http://dx.doi.org/10.1007/978-1-60327-216-2_2DOI Listing
April 2012

A phase II study of eribulin mesylate (E7389) in patients with advanced, previously treated non-small-cell lung cancer.

Clin Lung Cancer 2012 Jan 8;13(1):31-8. Epub 2011 Sep 8.

Virginia Cancer Specialists, INOVA Thoracic Oncology Program, Fairfax, VA 22031, USA.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1016/j.cllc.2011.06.010DOI Listing
January 2012

Dicentric (17;20)(p11.2;q11.2): an uncommon cytogenetic abnormality in myeloid malignancies.

Cancer Genet Cytogenet 2006 Oct;170(1):61-4

Laboratory of Cytogenetics, Quest Diagnostics Nichols Institute, 14225 Newbrook Drive, Chantilly, VA 20151, USA.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1016/j.cancergencyto.2006.04.013DOI Listing
October 2006

Extensive-stage small-cell lung cancer.

Semin Surg Oncol 2003 ;21(3):164-75

Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins, Baltimore, Maryland, 21231-1000, USA.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1002/ssu.10034DOI Listing
February 2004

Multidisciplinary management of lung cancer.

N Engl J Med 2004 Jan;350(4):379-92

Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins, Baltimore, MD 21231-1000, USA.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1056/NEJMra035536DOI Listing
January 2004

Differentiation therapy.

Curr Opin Pharmacol 2003 Aug;3(4):338-43

Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins, 1650 Orleans Street, CRB Room 1M89, Baltimore, MD 21231, USA.

View Article

Download full-text PDF

Source
August 2003

The use of chemotherapy in soft-tissue sarcomas.

Oncologist 2002 ;7(4):348-59

Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins, Baltimore, Maryland 21231, USA.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1634/theoncologist.7-4-348DOI Listing
October 2002